Neuroblastoma (NB) is an embryonal cancer of the sympathetic nervous system observed in early childhood, characterized by a broad spectrum of clinical behaviors, ranging from spontaneous regression to fatal outcome despite aggressive therapies. NB accounts for 8-10% of pediatric cancers and 15% of the deaths attributable to malignant conditions in children. Interestingly, NB may occur in various contexts, being mostly sporadic but also familial or syndromic. This review focuses on recent advances in the identification of the genes and mechanisms implicated in NB pathogenesis. Although the extensive characterization of the genomic aberrations recurrently observed in sporadic NBs provides important insights into the understanding of the clinical heterogeneity of this neoplasm, analysis of familial and syndromic cases also unravels essential clues on the genetic bases of NB. Recently, the ALK gene emerged as an important NB gene, being implicated both in sporadic and familial cases. The identification of gene expression signatures associated with patient's outcome points out the potential of using gene expression profiling to improve clinical management of patients suffering from NB. Finally, based on recent observations integrating genomic analyses, biological data and clinical information, we discuss possible evolution/ progression schemes in NB.
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Neuroblastoma clinical features
Clinical presentation Neuroblastoma (NB) was first described more than one century ago, by three physicians including Robert Hutchison, William Pepper and James Homer Wright who recognized the neural nature of the tumor (Rothenberg et al., 2009) . NB is indeed a disease of the sympaticoadrenal lineage of the neural crest and tumors may develop at various sites along the sympathetic nervous system (Brodeur, 2003; Maris et al., 2007) . Although most primary tumors occur in the abdomen (65%), often in the adrenal medulla, other develop in the paraspinal sympathic ganglia, at various sites including neck (5%), chest (20%) and pelvis (5%). The clinical presentation of NB can be very heterogeneous as reported more than 30 years ago (Evans et al., 1971) . Until recently, the most widely used staging system was the international NB staging system (INSS) that classified NB tumors into five stages according to the clinical presentation and age. This INSS classification distinguished localized (stages 1 and 2), advanced locoregional disease (stage 3) or metastatic (stage 4 or 4s) tumors (Brodeur et al., 1993) (Figure 1) . A new system called International Neuroblastoma Risk Group Staging System (INRGSS), based on clinical criteria and image-defined risk factors, now classifies NB into L1 (localized disease without image-defined risk factors precluding surgical resection), L2 (localized disease with image-defined risk factors), M (metastatic tumors) and Ms (metastatic tumors with metastases confined to the skin, liver and/or bone marrow in children younger than 18 months of age) (Cohn et al., 2009; Monclair et al., 2009) . The signs and symptoms of NB are extremely variable, depending on age, primary tumor site, presence of metastasis and occasionally on associated paraneoplastic syndromes. Heterogeneity also characterizes the clinical course and outcome of NB patients: whereas a subset of tumors will undergo spontaneous regression, others show relentless progression in spite of multimodal treatment. The outcome of children with NB is extremely different according to the INSS stage, with long-term survival rates still lower than 40% for patients with a high-risk clinical phenotype (Figure 1 ).
Histology
An International Pathology Classification System (INPC), based on the Shimada classification, distinguishes favorable and unfavorable tumors depending on the degree of neuroblastic differentiation, the amount of Schwannian stromal content, the mitosis-karyorrhexis index (MKI) and the age at diagnosis (Shimada et al., 1999) . Schematically, the unfavorable group includes undifferentiated tumors or high MKI cases at any age, poorly differentiated tumors or intermediate MKI in children older than 18 months, differentiating tumor or low MKI over 60 months. The favorable group includes all the other cases as well as ganglioneuroma (GN) or ganglioneuroblastoma intermixed. The last category is nodular ganglioneuroblastoma, with well-defined areas of ganglioneuromatous and neuroblastic components, the prognosis of which is determined by evaluating differentiation and MKI of the neuroblastic component.
Mass screening
Most of NBs secrete catecholamine whose metabolites can be found in the urine including dopamine, vanillylmandelic acid and homovanillic acid. This property has an important diagnostic value and is also extremely useful for patient's follow-up. In the 1980-1990s it provided a rationale to propose mass screening programs for NB detection at birth or at 6-12 months of age, mainly in Japan, Quebec and Germany (Schilling et al., 2002; Yamamoto et al., 2002; Barrette et al., 2006) . Quite disappointingly, the main early observation of these programs was an overall increased incidence of NB without significant decrease in mortality. This therefore indicated that screening mainly detected NB that would otherwise have regressed spontaneously but was relatively inefficient for an early detection of clinically relevant highrisk cases. However, the recent results of a nationwide program in Japan, in which more than 15 million children were screened at 6 months between 1984 and 2003, may be more encouraging (Hiyama et al., 2008) . Indeed, though this report confirms the higher incidence of favorable NB in the screened cohort as compared with the unscreened, it also reports a decreased mortality in the screened group associated with a decreased incidence of stage 4 tumors. This therefore suggests that screening at 6 months may detect some cases that would otherwise evolve toward more aggressive tumors at a later age. Given these results and with the goal of decreasing overdiagnosis and increasing effectiveness, pilot screening programs at 18 months have recently been launched in Japan. Although encouraging it has to be kept in mind that the Hiyama study is retrospective and should hence be confirmed by a prospective, case-control study to fully document the benefit of screening (Maris and Woods, 2008) .
Epidemiology
NB prevalence is about one case in 7000-10 000 live births. There is no strong evidence for difference in disease occurrence according to ethnical origin. No Molecular pathogenesis of peripheral neuroblastic tumors I Janoueix-Lerosey et al major risk factor was identified with respect to the potential role of parental occupation and of environmental factors in the pre-and perinatal periods (reviewed in (Heck et al., 2009) ). More convincingly, a recent study investigating the role of birth characteristics, congenital malformations and maternal reproductive history reported a very significant association of NB with congenital malformation in children less than 1 year (Munzer et al., 2008) .
Hereditary predisposition to NB
A familial history of NB is observed in about 1% of patients. A survey of 426 successive NB cases at the Institut Gustave Roussy in France identified a positive family history of NB or GN in 5 of the 426 cases (1.2%) (Shojaei-Brosseau et al., 2004) . In this cohort, the risk of NB among sibs was estimated at 0.2% (95% CI ¼ 0.004-1.0%) and penetrance in hereditary cases was estimated at 11.4%. NB pedigrees are usually consistent with a dominant autosomal pattern of inheritance with incomplete penetrance. A remarkable heterogeneity of the clinical presentation is observed within pedigrees in terms of age at diagnosis, histology and aggressiveness.
Two main neural-crest-derived conditions are associated with an increased risk to develop NB: Hirschsprung's disease, a developmental disorder characterized by an absence of ganglion cells in the distal colon resulting in functional obstruction and Ondine's curse, also named Congenital Central Hypoventilation Syndrome, a disorder characterized by a failure of the autonomic control of ventilation during sleep. The two last diseases are frequently associated and most cases are linked to mutation of the PHOX2B gene. Interestingly, associations between neuroblastic tumors and various 'neuro-cardio-facial-cutaneous' syndromes, including Noonan and Costello syndromes, as well as neurofibromatosis type 1, defined by the constitutive activation of the RAS-MAPK pathway (Bentires-Alj et al., 2006) , have been also reported (Denayer et al., 2008) .
PHOX2B and NB predisposition
The paired-like homeobox gene PHOX2B, localized at 4p12, encodes a transcription factor composed of 314 AA (Figure 2 ), which is a main regulator of the development of the autonomous system. This is underlined by the death in utero of homozygous null mice with absence of autonomic, enteric, sympathetic and parasympathetic ganglia (Pattyn et al., 1999) . Polyalanine expansions and frameshift mutations of PHOX2B gene were initially identified in Congenital Central Hypoventilation Syndrome (Amiel et al., 2003) . Subsequently, missense mutations, affecting residues localized in the homeodomain of PHOX2B, were described in two NB families (Trochet et al., 2004) . The association of PHOX2B mutation with NB predisposition was confirmed by various groups that also reported missense or frameshift mutations outside the homeodomain (Figure 2) (Mosse et al., 2004; McConville et al., 2006; Raabe et al., 2007) . A recent survey of the genotypephenotype correletions performed on 174 patients affected with Congenital Central Hypoventilation Syndrome, either isolated or associated with Hirschsprung's disease and/or neuroblastic tumors confirmed that NB predisposition was mainly linked to missense and frameshift mutations (Trochet et al., 2005b) . Although the involvement of PHOX2B in familial cases of NB is compelling, its contribution to the development of sporadic NB is much less obvious as somatic mutations are extremely rare (van Limpt et al., 2004; McConville et al., 2006; Raabe et al., 2007) .
Several studies have shown that the various PHOX2B mutations lead to stable mutant proteins (Trochet et al., 2005a; Raabe et al., 2007) , however, the molecular mechanisms underlying the role of these mutations in NB predisposition remain unclear. The observations that most frameshift and missense mutations decrease or abolish the in vitro transactivation activity of PHOX2B on the dopamine-b-hydroxylase promoter and can interfere with cellular differentiation suggest that defects in normal developmental and differentiation pathways may contribute to NB predisposition (Trochet et al., 2005a (Trochet et al., , 2009 Raabe et al., 2007) .
Germline ALK mutations in NB families
More recently, the ALK gene was identified as a second NB predisposition gene (see section below for the description of ALK gene). The group of J Maris used a linkage analysis approach to delineate a putative NB gene-encoding chromosomal region at 2p23-p24. Within this large region, ALK was considered as a strong candidate and further analyses identified 8 germline mutations out of the 20 studied families . Our group also documented ALK germline mutations in NB pedigrees (Janoueix-Lerosey et al., 2008) . Three types of germline mutations have been described to date in NB families, the R1275Q mutation being the most frequent ( Figure 2 ). Although detailed clinical information is still lacking for several families, it is apparent that the penetrance of these mutations may be incomplete and that neuroblastic tumors of variable aggressiveness can be observed in ALK mutation carriers.
Other clues to NB susceptibility Germline mutations of NF1, ALK and PHOX2B, three genes implicated in nervous system development, do not account for all familial NB cases. Interestingly, various types of abnormal constitutional karyotypes have been observed in patients with NB, including constitutional copy number anomalies, balanced and unbalanced translocations as well as specific chromosome deletions (Mosse et al., 2003; Satge et al., 2003) . Although most genes targeted by such constitutional anomalies remain to be identified, the NBPF1 (Neuroblastoma Breakpoint Family) gene is worth being pointed out (Vandepoele et al., 2005 (Vandepoele et al., , 2008 . It encodes a member of a novel and intricate human gene family of unknown function and it was shown to be disrupted by a constitutional t(1;17)(p36.2;q11.2) translocation in an NB patient. Very interestingly, a 1q21.1 copy number variant encoding NBPF23, another member of this gene family, was recently shown by a genome-wide association study to be associated with NB susceptibility, with an odd ratio of 2.49 (Diskin et al., 2009 ). This recurrent involvement of NBPF family genes in NB susceptibility may indicate they have critical roles in NB development. In addition to the NBPF23 copy number variant, genome-wide association study also identified single nucleotide polymorphisms (SNPs) at chromosome band 6p22 within the putative FLJ22536 and FLJ44180 genes and at 2q35 within the BARD1 genes that were associated with a moderate risk to develop aggressive NB Capasso et al., 2009) . Indeed, the allelic odds ratios were 1.39-1.40 for the three consecutive SNPs at 6p22 and odds ratios were of 1.68 each for the two most significant SNPs at 2q35.
Somatic genetic changes in sporadic NB
Although NBs may occur in familial and syndromic contexts, most cases occur sporadically. With the aim to identify the genes and mechanisms implicated in NB development and/or progression, many groups including ours have carried out in-depth characterization of the genomic aberrations recurrently observed in spora- 
Numerical chromosome alterations
Numerical chromosome alterations, that is whole chromosome gains or losses, are frequently observed leading to ploidy variations, with DNA indexes in the near-triploid range. Although one may hypothesize that the underlying mechanism leading to such numerical chromosome variations is probably linked to a failure of chromosomes to properly segregate during mitosis, the precise molecular nature of this anomaly remains unknown. In contrast to diploidy or tetraploidy, neartriploidy is usually associated with a good outcome (Look et al., 1984 (Look et al., , 1991 Ladenstein et al., 2001; Schneiderman et al., 2008) . We recently confirmed the excellent survival of patients with tumors harboring exclusively whole chromosome copy number variations (type A tumors) (Janoueix-Lerosey et al., 2009).
Segmental copy number alterations
Segmental copy number alterations, mainly including deletions of chromosome 1p, 3p, 11q and gain of 1q, 2p and 17q, have been reported to occur recurrently in NB and to be usually associated with a poor outcome (Schleiermacher et al., 1994 Bown et al., 1999; Caron et al., 2001; Plantaz et al., 2001; Attiyeh et al., 2005) . Although strongly associated with MYCN amplification, 1p deletion is also observed in cases without such amplification. In contrast, 11q and 3p deletions are mainly observed in tumors without MYCN amplification (Plantaz et al., 2001) . Partial 17q gain is frequently observed in primary tumors exhibiting segmental alterations, whatever MYCN status. These recurrent segmental alterations are thought to lead to the loss of putative tumor suppressor genes and/or to the gain of oncogenes, the exact nature of which remains to be determined. Interestingly, the use of cytogenetic methods revealed that most of these acquired, focal copy number alterations were associated with unbalanced translocations Schleiermacher et al., 2003) . In 1994, Caron et al. suggested that nonhomologous mitotic recombination in the S/G2 phase of the cell cycle between 1p and 17q could be a mechanism leading to unbalanced t(1;17) translocation, associated with 1p deletion and 17q gain (Caron et al., 1994) . In such a model, after segregation of the derivatives in daughter cells and considering a selective advantage provided by the translocation, tumor formation will arise from the cells exhibiting the der(1)t(1;17). Another hypothesis relies on a defective intra-S checkpoint, or other defects in DNA maintenance or repair pathways that may serve as a starting point for breakinduced replication, a mechanism well described in the yeast Saccharomyces cerevisiae, that could lead to the accumulation of unbalanced translocations (Malkova et al., 1996) . Interestingly, we unambiguously established that unbalanced translocations in NB cell lines occur preferentially in early replicating regions (Schleiermacher et al., 2003; Janoueix-Lerosey et al., 2005) . Moreover, interstitial telomere sequences lying at chromosome breakpoints have been observed in NB cells, suggesting that a telomere maintenance pathway may also be altered in these cells . A thorough analysis of the S-phase checkpoint may help to understand the molecular basis of these closely linked replication and telomere abnormalities in NB cells.
Importantly, we recently demonstrated that the presence of segmental alterations, whatever their type, was the strongest predictor of relapse in NB patients and that the analysis of the overall genomic pattern, rather than the analysis of individual markers, should be included in future treatment stratification (JanoueixLerosey et al., 2009). Importantly, this study also clearly indicated that tumors with both numerical and segmental abnormalities (type D) shared the higher risk of relapse of segmental-only (type B) tumors. Tumors with MYCN amplification can either harbor segmental-only alterations (type C) or mixed, segmental and numerical, profiles (type E).
Genomic amplifications
Amplification of the MYCN oncogene at chromosome 2p24 is observed in about one fourth of NB cases and is associated with advanced-stage disease and rapid tumor progression (Seeger et al., 1985) . MYCN status is routinely used in clinical practice to assign therapeutic intensity. Although MYCN amplification is mainly observed cytogenetically as acentric autonomously replicating double minute chromosomes (dmins) in NB primary tumors, intrachromosomally homogeneously staining regions (hsrs) are predominatly observed in NB cell lines. The size of the MYCN amplicon varies from o30 kb to several megabases. The DDX1 and NAG genes have been shown to be co-amplified with MYCN in 50 and 20% of NB cases, respectively (George et al., 1997; Wimmer et al., 1999) . The MYCN protein belongs to the MYC oncoproteins family that are transcription factors of the basic-helix-loop-helix-zipper class (Adhikary and Eilers, 2005; Eilers and Eisenman, 2008; Meyer and Penn, 2008) . Interestingly, recent data show that high MYCN/c-MYC target gene expression is a hallmark of malignant NB progression and that c-MYC probably has a role in agressive tumors without MYCN amplification (Fredlund et al., 2008; Westermann et al., 2008) . Several lines of evidence indicate that overexpression of MYC proteins has a major role in oncogenesis through the deregulation of growth and proliferation (Vita and Henriksson, 2006) . In particular, transgenic mice overexpressing MYCN in neuroectodermal cells under the tyrosine hydroxylase promoter develop tumors in peripheral neural-crest-derived structures and show typical histopathologic features of human NB, therefore demonstrating that MYCN can contribute to the transformation of neuroblasts in vivo (Weiss et al., 1997; Chesler et al., 2007) . Unlike c-MYC, which is ubiquitous, MYCN has a very restricted expression pattern and is critical in the development of the peripheral and central nervous system. Mice homozygous for a targeted disruption of the MYCN gene die between 10.5 and 12.5 days of gestation with underdeveloped hearts and reduction of the cranial and spinal ganglia (Charron et al., 1992) . MYCN conditional disruption in neuronal progenitor cells further shows that this gene is essential during neurogenesis, affecting proliferation and differentiation of progenitor cells (Knoepfler et al., 2002) . Interestingly, in humans, germline mutations in or deletions of the MYCN gene have been shown to be responsible for the Feingold syndrome, a disease characterized by variable combinations of esophageal and duodenal atresias, microcephaly, learning disability, syndactyly and cardiac defect (van Bokhoven et al., 2005) . The observed mutations result in haploinsufficiency of both the canonical MYCN protein and of a shortened MYCN isoform (delta MYCN) (Marcelis et al., 2008) , suggesting that multiple aspects of early embryogenesis and postnatal brain growth in humans are tightly regulated by MYCN dosage.
Other regional amplifications targeting various sites, nonsyntenic with the MYCN locus and including 1p34, 1p36, 2p14, 5q33, 8q24, 11q13, 12q13-14 and 16q22 have been described in NB (Jinbo et al., 1989; Molenaar et al., 2003; Fix et al., 2004 Fix et al., , 2008 Su et al., 2004; Mosse et al., 2005 Mosse et al., , 2007 Van Roy et al., 2006; Carr et al., 2007) . None of these amplicons exhibits a recurrence as high as that of the MYCN amplicon and most often, they occur concomitantly with MYCN amplification (Fix et al., 2008) . Their contribution to the oncogenic transformation therefore remains uncertain at this time. Of interest, high-level amplifications of the ALK locus were reported by various groups in a subset of NB samples long before ALK gene emerged as a major actor of NB oncogenesis (Lamant et al., 2000; Miyake et al., 2002; Osajima-Hakomori et al., 2005; George et al., 2007; Fix et al., 2008) .
Somatic ALK activating mutations in sporadic NB Despite the extensive description of copy number alterations in NB, only a few mutations in bona fide cancer genes have been reported in NB primary tumors. The identification of somatic and activating mutations of the ALK gene last year undeniably represents a breakthrough in the understanding of NB pathogenesis George et al., 2008; Janoueix-Lerosey et al., 2008; Mosse et al., 2008) .
The ALK gene encodes a transmembrane receptor tyrosine kinase (RTK) comprising 1620 AA, preferentially expressed in the central and peripheral nervous systems (Chiarle et al., 2008) . The extracellular region of ALK comprises a 26-AA N-terminal signal peptide sequence, two MAM (for meprin, A5 protein and receptor protein tyrosine phosphatase mu) domains (264-427 and 480-626) that are thought to have adhesive function, one LDLa domain that is expected to form a binding site for LDL and calcium (453-471) and a glycin-rich region (816-940) (Palmer et al., 2009 ). The binding site for the two putative ALK ligands, pleiotrophin and midkine, has been mapped between residues 391 and 401 (Stoica et al., 2001 (Stoica et al., , 2002 Chiarle et al., 2008) . A transmembrane-spanning segment connects the extracellular region with the intracellular region that includes a juxtamembrane segment (1058-1122), the tyrosine kinase domain (1122-1376) and the C-terminal region. The function of the full-length ALK receptor is poorly understood (Chiarle et al., 2008) . Mice homozygous for a deletion of the ALK tyrosine kinase domain have a normal appearance and no obvious tissue abnormality, but preliminary observations detected an increase in the number of the progenitor cells of the hippocampus and modifications in adult brain function (Bilsland et al., 2008) . The ALK protein has been described as a new member of the growing family of dependence receptors, which may exert antagonist functions, that is apoptotic or antiapoptotic, depending on the absence or presence of the ligand (Mourali et al., 2006) . This property of the ALK receptor needs to be confirmed in vivo and requires a true identification and characterization of the ALK ligand(s).
To date, five papers reported a total of 54 ALK mutations, affecting 12 different residues with two hotspots of mutations at positions 1174 and 1275, in 680 sporadic NB cases that have been analyzed (8% of cases) (Figure 3) (Caren et al., 2008; Chen et al., 2008; George et al., 2008; Janoueix-Lerosey et al., 2008; Mosse et al., 2008) . Although the three dimensional structure of the ALK protein has not been resolved to date, homology models with other RTK indicate that the F1174 residue is located at the end of the C helix and the R1275 residue is part of the activation loop. Interestingly, the spectrum of somatic and germline ALK mutations are different. Indeed, up to now, mutations affecting the F1174 residue have not been detected in the germline, possibly related to an embryonal lethality, whereas mutations of the R1192 residue have been observed in familial but not in sporadic forms of NB. This suggests differences in ALK signaling through specific mutations, which remain to be further characterized by functional analyses.
The existence of a potential link between ALK mutations and the behavior of the tumor remains to be fully determined. In our screening of sporadic tumors, ALK mutations did not correlate with aggressive forms of NB (stage 4). However, the other three groups (Caren et al., 2008; Chen et al., 2008; Mosse et al., 2008) reported a higher frequency of ALK mutations in advanced stages of the disease. Interestingly, a recent meta-analysis for ALK mutation status in relation to genomic and clinical parameters performed on 709 cases indicated that mutations were found in both low-risk and high-risk NB tumors and that the F1174 mutations were significantly overrepresentated in tumors presenting with MYCN amplification (Frank Speleman, personal communication). Combined occurrence of these two alterations was associated with a particular poor outcome.
The group of J Maris has previously reported that ALK is differentially expressed in human primary NB with higher expression generally seen in the most aggressive subset of tumors . In agreement with this observation, ALK protein expression has recently been shown to be significantly upregulated in adavanced/metastatic tumors compared with localized NB (Passoni et al., 2009) . Moreover, two reports suggest that higher levels of ALK mRNA are expressed in NB samples harboring ALK mutations as compared with ALK wild type (Caren et al., 2008; Mosse et al., 2008) . The analysis of larger series of NBs will undoubtedly provide further information with respect to the precise relationship between ALK mutations, ALK expression, other genomic alterations and tumor phenotype including clinical presentation and outcome.
Several lines of evidence indicate that the observed mutations are kinase activating and oncogenic: (1) high levels of the Y1586-or Y1604-phosphorylated form of ALK, (that have been associated earlier with activation of the ALK protein (Rikova et al., 2007) ) are detected in NB cell lines harboring mutated ALK George et al., 2008; Janoueix-Lerosey et al., 2008; Mosse et al., 2008) ; (2) the mutant versions of ALK exhibit a strong in vitro kinase activity (JanoueixLerosey et al., 2008) ; (3) the F1174L and R1275Q mutated versions of ALK promote cytokine-independent growth of the BaF3 cell line, an immortalized murine bone marrow-derived pro-B-cell line the growth and proliferation of which depends on the presence of IL-3 (George et al., 2008) ; (4) overexpression of the F1174L and K1062M mutants in NIH3T3 cells induce the formation of foci in soft agar assays and of subcutaneous tumors in nude mice . Importantly, the knockdown of ALK expression in ALK-mutated cells, but also in several cell lines over-expressing an apparently wild-type ALK, leads to a dramatic decrease in cell proliferation (Janoueix- Lerosey et al., 2008; Mosse et al., 2008; Passoni et al., 2009) . In agreement with these observations, NB cell lines harboring activating ALK mutations respond to the ALK inhibitors NVP-TAE684 and PF-02341066 (vide infra) (George et al., 2008; Janoueix-Lerosey et al., 2008) . Finally, although the exact link between MYCN and ALK remains to be defined, the effect of siRNA or shRNA targeting ALK was observed in a number of cell lines also presenting with MYCN amplification including IMR32, CLB-MA, KELLY and IMR5 (JanoueixLerosey et al., 2008; Mosse et al., 2008; Passoni et al., 2009) . Altogether, these data provide a strong molecular rationale for ALK-targeted therapy in NB.
The ALK gene has been previously implicated in other human malignancies: indeed, the ALK gene is recurrently involved in gene fusions induced by chromosome translocations in different types of cancer including anaplastic large cell lymphomas (Morris et al., 1994) , diffuse large B-cell lymphomas (Adam et al., 2003; Onciu et al., 2003) , inflammatory myofibroblastic tumors (Griffin et al., 1999) and a subset of non-small cell lung cancers (Soda et al., 2007) . Most fusion proteins studied to date are characterized by constitutive activation of the ALK tyrosine kinase activity through spontaneous dimerization and induce cell transformation (Chiarle et al., 2008; Palmer et al., 2009) . The potent oncogenic activity of the NPM(nucleophosmin)-ALK and EML4-ALK fusions have been demonstrated in mouse models by the occurrence of lymphoma and lung adenocarcinoma in transgenic mice expressing NPM-ALK and EML4-ALK, respectively (Chiarle et al., 2003; Turner et al., 2003; Soda et al., 2008) . Oncogenic signaling through the NPM-ALK protein has been extensively studied and recently reviewed (Chiarle et al., 2008; Palmer et al., 2009) . The pathways engaged by NPM-ALK include the PLCg, PI3K/AKT, RAS/MAPK and JAK/STAT pathways. The other ALK-fusion proteins are assumed to function mainly in a similar manner.
As mentioned earlier, several NB cell lines presenting with ALK amplification exhibited constitutively activated ALK. In these samples, it has been shown that activated ALK forms a stable complex with hyperphosphorylated ShcC, an adaptator protein, and The success of various tyrosine kinase inhibitors in different cancers, as well as the expanding number of human malignancies, both in children and adults, involving aberrant ALK activity encourages the search for ALK-selective small-molecules inhibitors. Different categories of putative ALK inhibitors have been explored and recently reviewed (Webb et al., 2009 ). The two inhibitors, NVP-TAE684 and PF-2341066, targeting the ATP-binding pocket of ALK thereby blocking ATP binding, have been identified through small-molecule library screenings (Galkin et al., 2007; Zou et al., 2007; McDermott et al., 2008) . Unlike NVP-TAE684 that is not currently being tested as a clinical agent, the PF-2341066 compound, which is a dual inhibitor targeting both ALK and MET kinases, has entered phase I clinical trials (www.ClinicalTrials.gov) and is administered orally to patients with advanced cancer. At the 2009 ASCO Annual Meeting, Wood and colleagues reported that PF-02341066 caused complete regression of ALK R1275Q NB xenografts, but caused only minimal growth delay in ALK F1174L and WT xenografts. Therefore, the development of more than one ALK-selective inhibitor will likely be required to optimally treat NB patients. Further important questions remain to be elucidated with respect to the implication of ALK in NB pathogenesis. Is the involement of ALK in NB limited to the cases with bona fide mutations or amplification? The issues of ALK ligand(s) and signaling pathways are especially crucial in the understanding of ALK function because abnormalities of ALK ligand(s) or downstream targets may constitute alternative mechanisms to ALK activation. The development of mouse models will be critical to document the precise role of ALK mutations in NB oncogenesis. Such models should be extremely useful and powerful for testing anti-ALK therapeutics.
Expression analysis
Numerous groups have used gene expression profiling to seek for gene signatures that may be helpful to classify NB depending on their favorable or unfavorable outcomes (Berwanger et al., 2002; Ohira et al., 2005; Schramm et al., 2005; Asgharzadeh et al., 2006; Oberthuer et al., 2006; Wang et al., 2006) . Importantly, these different publications clearly establish that gene expression profiles strongly differ between favorable and aggressive cases therefore pointing out the potential of gene profiling in clinical setting.
The genes involved in the prognostic signature differ from one report to the other, a difference that may be attributed to the relatively small size of the series, to the different array platforms and to the distinct types of bioinformatic analyses that were used in these studies. However, datamining of these prognostic gene expression signatures revealed some important pathways that may have critical roles in tumor aggressiveness. These include high MYC or b-catenin pathway activity, high expression of cell cycle and/or chromosome segregation genes and low expression of late neural differentiation genes (Krasnoselsky et al., 2005; Fredlund et al., 2008; Liu et al., 2008; Westermann et al., 2008; Bourdeaut et al., 2009) . In an interesting meta-analysis, Vermeulen et al. (2009) recently re-analyzed the seven published micro-array gene expression studies that totalize 690 patients with a uniform method, that is prediction analysis of micro-arrays, and consequently generated seven new prognostic gene sets. Fifty-nine genes were then selected from these seven sets and their expression level was investigated by quantitative RT-PCR in two large cohorts of NB patients from Europe and the US. In both the cohorts this multi-gene expression signature distinguished high-from low-risk patients. Importantly, multivariate logistic regression analyses showed that the signature was still an independent and statistically significant parameter in models adjusted for MYCN status, age, INSS stage and ploidy. Combined with DNA profiles, it can be anticipated that the analysis of such gene expression signatures that can be easily assessed in a clinical setting by quantitative RT-PCR, may rapidly constitute an essential parameter for the clinical management of patients.
A strong interest in the role of microRNAs in NB development has recently emerged. Two recent studies have reported differential microRNA expression in NB (Welch et al., 2007; Schulte et al., 2008) . Although the size of these series was too limited to address the predictive value of microRNA expression profiles it can be foreseen that further studies will identify microRNAs linked to aggressiveness. Some micro-RNAs that may be regulated by MYCN or by retinoic acid have been described (Fukuda et al., 2005; Laneve et al., 2007; Welch et al., 2007) . Mir-34-A, a direct target of p53 that regulates cell cycle arrest and apoptosis, is downregulated in NB through the loss of 1p36 and is expected to have a role in tumorigenesis (Welch et al., 2007; Cole et al., 2008; Wei et al., 2008) .
Progression schemes in NB
As mentioned above, the genetic analysis of NB samples identified several genomic profiles characterized by specific abnormalities and associated with distinct prognosis Vandesompele et al., 2005; Michels et al., 2007; Mosse et al., 2007; Tomioka et al., 2008; Janoueix-Lerosey et al., 2009 ). Whether these profiles distinguish different, unrelated entities, or whether they constitute snapshots at different times of one entity that may evolve from one profile to the other, is important. Both hypotheses may be actually valid. On the one hand, it seems very unlikely that good prognosis pseudo-triploid tumors may evolve into highly aggressive diploid tumors. These two categories rather constitute clearly distinct entities. On the other hand, some recent data argue that, in some occasions, triploid tumors with only numerical chromosome changes (type A) may secondarily acquire segmental alterations and progress into more aggressive triploid tumors with mixed profiles (triploid type D) (Figure 4) . First, the genetic background of these triploid type D cases is highly related to that of purely numerical cases, with numerical changes concerning the same chromosomes (G Schleiermacher et al., unpublished data) . Secondly, the study of paired samples at diagnosis and at relapse clearly shows that segmental alterations may appear at relapse in cases that were purely numerical at diagnosis (G Schleiermacher et al., unpublished data) . It is therefore likely that some tumors with a mixed numerical and segmental profile arose through evolution of tumors with a purely numerical profile at onset. In this scheme, it is of interest to underline that the age at diagnosis of mixed profile tumors is significantly higher than the age at diagnosis of numerical-only cases therefore suggesting that this progression may require a relatively long time. Importantly, such a progression scenario may account for the results of recent screening programs in Japan that were described above. Indeed, though it is clear that de novo, rapidly developing aggressive tumors can hardly be detected by screening programs at 6 months, slowly growing type A tumors that have a risk to ultimately progress into aggressive type D may be detected at an early stage (Figure 4) . Consequently, this may result in the decreased frequency of NB cases later in life that is noted in the aforementioned report (Hiyama et al., 2008) . In that situation, one would expect that screening does not decrease the number of segmental-only cases but rather decreases the number of cases with mixed genetic profiles.
Although most NB are presumed to arise de novo, without a GN premalignant step, the evolution from GN into NB may nevertheless be possible. Indeed, some lines of arguments suggest that such a progression may occur. First, X-methylation analysis indicates that though most GNs are polyclonal, a subset of cases harbors a skewed X-inactivation pattern highly suggestive of monoclonality (Bourdeaut et al., 2008) . A second argument comes from the analysis of nodular ganglioneuroblastoma that presents NB nodules within a stroma-rich background. In those cases, the Schwannian component does not harbor the genetic abnormalities observed in the neuroblastic area, indicating that it does not derive from this last component (Bourdeaut et al., 2008) . However, in most cases that we studied, the Schwannian and neuroblastic components were monoclonal with identical X-methylation profiles therefore strongly suggesting that both components were derived from a common progenitor. A likely hypothesis is therefore that monoclonal expansion of a glial-neural precursor first gave rise to a GN with both Schwannian and ganglionic components. Secondarily, through the occurrence of genetic alterations, neural cells became fully transformed giving rise to NB. Although it remains (Bourdeaut et al., 2008) . Neural cells may then acquire two types of genetic alterations. Occurrence of numerical chromosome abnormalities gives rise to slow-growing pseudo-triploid tumors without abnormality of chromosome structure (good prognosis neuroblastoma type A). At the opposite, unbalanced translocations, which can be associated or not with MYCN amplification, lead to aggressive di/tetraploid tumor with no or very few whole chromosome numerical changes (types B and C). Secondarily, type A tumors may acquire additional segmental alterations that lead to aggressive type D or E tumors. Aggressive NB can then occur directly from the neural precursor (de novo occurrence) or after evolution of a good prognosis type A tumor (secondary occurrence).
to be clearly demonstrated that GN can evolve into NB, this seems a likely hypothesis at least in a subset of cases. The observation that PHOX2B mutation carriers can have tumors with very different aggressiveness, including GN, also supports the hypothesis of benign tumors secondarily evolving into more aggressive NB in some cases. It remains to be documented whether ALK mutation also predisposes to GN but it was already stated above that a large spectrum of aggressiveness can also be noted in ALK mutation carriers. Altogether, these different observations lead to propose the model indicated in Figure 4 . The real frequency of these progression scenarios remains to be defined. GN may in some occasions be monoclonal and account for the clonal expansion of a common progenitor that still have the ability to differentiate into neural and glial lineages (this may constitute a first hit in neuroblastic tumor development). Secondarily, the occurrence of new genetic alterations may lead to full transformation into NB with a complete block of differentiation and hence constitute a second hit in NB development. Finally, purely numerical cases may evolve, with a frequency that remains to be established, into more aggressive tumors with mixed numerical and segmental profiles.
Such a model is reminiscent of some progression schemes in hematopoietic malignancies and particularly in chronic myeloid leukemia (CML) (Melo and Barnes, 2007) . Indeed, at the chronic phase of the disease to which we may tentatively compare the monoclonal GN stage, CML monoclonal cells retain the ability to differentiate into the different hematopoietic lineages. Subsequently, CML cells acquire additional genetic lesions and progress into acute leukemia with lost of the ability to differentiate terminally. In our model, this chronic to acute phase progression may correspond to the GN to NB evolution for which the nodular ganglioneuroblastoma may represent a transition stage. However, as most acute leukemias do not rise from a previous CML, the scenario that is hypothesized here for NB may only account for a minority of tumors. In most cases NB would arise de novo, without prior GN phase.
Conclusion
Biological knowledge is essential to understand NB heterogeneity with the aim to improve patients' management, with respect to diagnosis, prognosis and therapeutics. The identification of homogeneous groups of patients is critical to provide optimal therapeutic strategies and, probably in a near future, new tumor parameters, defined through large genomic and expression profiling studies, will be taken into account to assign therapeutic strategies.
Understanding of familial and syndromic NB recently has made considerable progress with the identification of PHOX2B and ALK as NB susceptibility genes. Interestingly, both genes are implicated in nervous system development, underlying the link between development and cancer in this pediatric neoplasm. Furthermore, genome-wide association study studies still broaden the spectrum of NB susceptibility with the discovery of various SNPs associated with an increased risk to develop tumors.
Even more importantly, the ALK receptor emerged as a potential therapeutic target through the characterization of somatic and activating mutations in sporadic NB. Although the link between ALK mutations and the other genomic aberrations present in NB cells still remains to be elucidated, in vitro experiments demonstrated that downregulation of the ALK receptor leads to a marked decrease in cell proliferation. These observations are consistent with the phenomenon of 'oncogene addiction,' stipulating that growth and survival of cancer cells may be impaired by the inactivation of a single oncogene, despite the occurrence of multiple genetic abnormalities (Weinstein, 2002; Weinstein and Joe, 2008) . Such an addiction provides a molecular rationale for targeted therapies based on ALK-selective small-molecules inhibitors, which are currently under development. Studies on the use of imatinib to inactivate BCR-ABL or c-KIT in CML or gastrointestinal stromal tumor patients illustrate the fantastic power of such approaches to treat patients.
Up to now, there was little evidence, if any, in the literature indicating that genetically or biologically favorable neuroblastic tumors may evolve into unfavorable cases. Some of our recent data indicate that such progression schemes are actually possible. Although the exact frequency of such scenarios remains to be determined, they have important clinical consequences and should therefore be considered.
In a review published in 2003 (Brodeur, 2003) , Garrett Brodeur noted that 'Few tumors have engendered as much fascination and frustration for clinical and laboratory investigators as NB, the most common and deadly solid tumor of childhood.' Our feeling is that fascination will still remain because of the huge heterogeneity of this tumor, with respect to biology, genetics and outcome, whereas we hope that frustration will continue to decrease with the improvement of the understanding of NB pathogenesis and targeted therapies emerging.
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